You are here

  • Home
  • Archive
  • Volume 12, Issue 2
  • Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent strokeCommentary

Article Text

Article menu
Download PDFPDF
Treatment
Review: immediate antiplatelet therapy after acute ischaemic stroke reduces death or dependency and risk of recurrent stroke

https://doi.org/10.1136/ebn.12.2.49

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    P A Sandercock

    Dr P A Sandercock, University of Edinburgh, Edinburgh, UK; peter.sandercock@ed.ac.uk

    QUESTION

    What is the efficacy and safety of immediate antiplatelet therapy after acute ischaemic stroke?

    REVIEW SCOPE

    Included studies compared antiplatelet therapy, including aspirin, abciximab, heparin, and ticlopidine (started within 14 d of stroke) with placebo or no treatment in patients with acute ischaemic stroke. Studies of antiplatelet therapy after primary intracerebral or subarachnoid haemorrhage, or drugs with multiple modes of action (eg, piracetam, prostacyclin, and oxpentifylline) were excluded. Outcomes included death or dependence on others for activities of daily living 1 month after stroke, all-cause mortality, deep venous thrombosis, pulmonary embolism, recurrent stroke, and intracranial and extracranial haemorrhage.

    REVIEW METHODS

    Medline, EMBASE/Excerpta Medica, …

    View Full Text

    Footnotes

    • Source of funding: Wellcome Trust and Medical Research Council.